Abliva AB
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.abliva.com
Clinical Trials
5
Active:2
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 180
- Registration Number
- NCT05650229
- Locations
- 🇺🇸
Akron Children's Hospital, Akron, Ohio, United States
🇺🇸The University of Texas Health Science Center at Houston, Houston, Texas, United States
🇧🇪Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel, Brussel, Belgium
Drug-drug Interaction Study of KL1333 in Healthy Subjects
Phase 1
Completed
- Conditions
- Mitochondrial Disease
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 14
- Registration Number
- NCT04643249
- Locations
- 🇬🇧
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
Phase 1
Completed
- Conditions
- MELAS SyndromeMitochondrial DiseasesMitochondrial MyopathiesMitochondrial Respiratory Chain Deficiencies
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 72
- Registration Number
- NCT03888716
- Locations
- 🇬🇧
Covance Leeds, Leeds, West Yorkshire, United Kingdom
🇬🇧UCL, London, United Kingdom
News
Pharming Group to Acquire Abliva in $66.1 Million Deal, Bolstering Mitochondrial Disease Pipeline
Pharming Group N.V. has announced a public cash offer to acquire Abliva AB for approximately US$66.1 million, strengthening its pipeline.